Prescription opioid abuse: Challenges and opportunities for payers

American Journal of Managed Care

Volumn 19, Issue 4, 2013, Pages 295-302

  Katz, Nathaniel P ^a   Birnbaum, Howard ^b   Brennan, Michael J ^c   Freedman, John D ^d   Gilmore, Gary P ^e   Jay, Dennis ^f   Kenna, George A ^g   Madras, Bertha K ^h,i   McElhaney, Lisa ^j   Weiss, Roger D ^h,k   White, Alan G ^b  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ANALYSIS GROUP   (United States)

^c BRIDGEPORT HOSPITAL   (United States)

^d Freedman Healthcare Consulting   (United States)

^e UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^f Coalition Against Insurance Fraud ^*  (United States)

^g BROWN UNIVERSITY   (United States)

^h HARVARD MEDICAL SCHOOL   (United States)

ⁱ MASSACHUSETTS GENERAL HOSPITAL   (United States)

^j National Association of Drug Diversion Investigators   (United States)

^k MCLEAN HOSPITAL   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

OPIATE;

HEALTH CARE POLICY; HUMAN; LAW ENFORCEMENT; OPIATE ADDICTION; PRESCRIPTION; PRIORITY JOURNAL; REVIEW; RISK MANAGEMENT;

ANALGESICS, OPIOID; COST CONTROL; HUMANS; MANAGED CARE PROGRAMS; PRESCRIPTION DRUGS; RISK MANAGEMENT; SUBSTANCE ABUSE DETECTION; SUBSTANCE-RELATED DISORDERS;

EID: 84877743834     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (81)

1. Executive Office of the President of the United States. Epidemic: responding to America's prescription drug abuse crisis. http://www.whitehouse. gov/sites/default/files/ondcp/issues-content/prescriptiondrugs/rx abuse plan.pdf. Published 2011.
2. Nonmedical users of pain relievers: characteristics of recent initiates. The NSDUH Report: Office of Applied Studies, Substance Abuse and Mental Health Services Administration, 2006.
3. Substance Abuse and Mental Health Services Administration. Results from the 2009 National Survey on Drug Use and Health: volume I: summary of national findings (Office of Applied Studies, NSDUH Series H-38A, HHS Publication No. SMA 10-4586Findings). Rockville, MD: 2010.
4. Katz NP, Adams EH, Benneyan JC, et al. Foundations of opioid risk management. Clin J Pain. 2007;23(2):103-118. (Pubitemid 46145457)
5. Paulozzi LJ, Budnitz DS, Xi Y. Increasing deaths from opioid analgesics in the United States. Pharmacoepidemiol Drug Saf. 2006;15(9):618-627. (Pubitemid 44404658)
6. Paulozzi LJ, Ryan GW. Opioid analgesics and rates of fatal drug poisoning in the United States. Am J Prev Med. 2006;31(6):506-511. (Pubitemid 44880582)
7. Kochanek KD, Xu J, Murphy SL, Miniño AM, Kung H-C. Deaths: preliminary data for 2009. Ntl Vital Stat Rep. 2011;59(4):1-51.
8. Substance Abuse and Mental Health Services Administration, Office of Applied Studies. Drug Abuse Warning Network, 2007: National Estimates of Drug-Related Emergency Department Visits. http://www.samhsa.gov/data/2k10/DAWN/ ED2007/DAWN2k7ED.htm. Rockville, MD: 2007.
9. Leider HL, Dhaliwal J, Davis EJ, Kulakodlu M, Buikema AR. Healthcare costs and nonadherence among chronic opioid users. Am J Manag Care. 2011;17(1):32-40.
10. White AG, Birnbaum HG, Mareva MN, et al. Direct costs of opioid abuse in an insured population in the United States. J Manag Care Pharm. 2005;11(6):469-479.
11. White AG, Birnbaum HG, Rothman DB, Katz N. Development of a budget-impact model to quantify potential cost savings from prescription opioids designed to deter abuse or ease of extraction. Appl Health Econ Health Policy. 2009;7(1):61-70.
12. McAdam-Marx C, Roland CL, Cleveland J, Oderda GM. Costs of opioid abuse and misuse determined from a Medicaid database. J Pain Palliat Care Pharmacother. 2010;24(1):5-18.
13. Strassels SA. Economic burden of prescription opioid misuse and abuse. J Manag Care Pharm. 2009;15(7):556-562.
14. GAO. Medicaid: fraud and abuse related to controlled substances identified in selected states, GAO-09-957. Washington, DC.
15. GAO. Medicare Part D: Instances of questionable access to prescription drugs, GAO-11-699. Washington, DC.
16. Centers for Medicare & Medicaid Services. National Health Expenditure Data: national health expenditures by type of service and source of funds, CY 1960-2008. Baltimore, MD: 2008.
17. Kaiser Family Foundation. Prescription drug trends. 2008.
18. Caudill-Slosberg MA, Schwartz LM, Woloshin S. Office visits and analgesic prescriptions for musculoskeletal pain in US: 1980 vs. 2000. Pain. 2004;109(3):514-519. (Pubitemid 38638730)
19. The National Center on Addiction and Substance Abuse (CASA) at Columbia University. CASA's analysis of the 2000 National Prescription Audit Plus data system [data file]. Fairfield, CT: IMS Health; 2003.
20. Under the counter: the diversion and abuse of controlled prescription drugs in the U.S. New York, NY: 2005.
21. National Drug Intelligence Center. Drug Enforcement Administration. US Department of Justice. National prescription drug threat assessment. 2009.
22. Birnbaum HG, White AG, Reynolds JL, et al. Estimated costs of prescription opioid analgesic abuse in the United States in 2001: a societal perspective. Clin J Pain. 2006;22(8):667-676. (Pubitemid 44434948)
23. Ruetsch C. Empirical view of opioid dependence. J Manag Care Pharm. 2010;16(1, suppl B):S9-S13.
24. National Institute on Drug Abuse. The economic costs of alcohol and drug abuse in the United States-1992. 1992.
25. Joranson DE, Gilson AM. Drug crime is a source of abused pain medications in the United States. J Pain Symptom Manage. 2005;30(4): 299-301. (Pubitemid 41527112)
26. Executive Office of the President Office of National Drug Control Policy. The economic costs of drug abuse in the United States: 1992- 2002. 2004.
27. The National Center on Addiction and Substance Abuse at Columbia University. Shoveling up II: the impact of substance abuse on federal, state and local budgets (Appendix A: State and Local Survey Instrument Only). May 2009.
28. Lin JJ, Alfandre D, Moore C. Physician attitudes toward opioid prescribing for patients with persistent noncancer pain. Clin J Pain. 2007;23(9):799-803. (Pubitemid 351339417)
29. Nwokeji ED, Rascati KL, Brown CM, Eisenberg A. Influences of attitudes on family physicians' willingness to prescribe long-acting opioid analgesics for patients with chronic nonmalignant pain. Clin Ther. 2007;29(suppl):2589-2602. (Pubitemid 350299461)
30. Wolfert MZ, Gilson AM, Dahl JL, Cleary JF. Opioid analgesics for pain control: Wisconsin physicians' knowledge, beliefs, attitudes, and prescribing practices. Pain Med. 2010;11(3):425-434.
31. Gilson AM, Maurer MA, Joranson DE. State medical board members' beliefs about pain, addiction, and diversion and abuse: a changing regulatory environment. J Pain. 2007;8(9):682-691. (Pubitemid 47362841)
32. White AG, Birnbaum HG, Schiller M, Tang J, Katz NP. Analytic models to identify patients at risk for prescription opioid abuse. Am J Manag Care. 2009;15(12):897-906.
33. Katz N, Panas L, Kim M, et al. Usefulness of prescription monitoring programs for surveillance - analysis of Schedule II opioid prescription data in Massachusetts, 1996-2006. Pharmacoepidemiol Drug Saf. 2010; 19(2):115-123.
34. Jan SA. Patient perspective, complexities, and challenges in managed care. J Manag Care Pharm. 2010;16(1, suppl B):S22-S25.
35. Mitchell L. Pharmacy lock-in program promotes appropriate use of resources. J Okla State Med Assoc. 2009;102(8):276.
36. Oklahoma Health Care Authority. SoonerCare pharmacy lock-in program promotes appropriate use of medications. 2009.
37. Katz NP, Adams EH, Chilcoat H, et al. Challenges in the development of prescription opioid abuse-deterrent formulations. Clin J Pain. 2007;23(8):648-660. (Pubitemid 47462170)
38. Schneider JP, Matthews M, Jamison RN. Abuse-deterrent and tamper-resistant opioid formulations: what is their role in addressing prescription opioid abuse? CNS Drugs. 2010;24(10):805-810.
39. Parente ST, Kim SS, Finch MD, et al. Identifying controlled substance patterns of utilization requiring evaluation using administrative claims data. Am J Manag Care. 2004;10(11, pt 1):783-790. (Pubitemid 39518523)
40. Barry DT, Irwin KS, Jones ES, et al. Opioids, chronic pain, and addiction in primary care. J Pain. 2010;11(12):1442-1450.
41. Edlund MJ, Martin BC, Fan MY, et al. Risks for opioid abuse and dependence among recipients of chronic opioid therapy: results from the TROUP Study. Drug Alcohol Depend. 2010;112(1-2):90-98.
42. Edlund MJ, Martin BC, Devries A, Fan MY, Braden JB, Sullivan MD. Trends in use of opioids for chronic noncancer pain among individuals with mental health and substance use disorders: the TROUP study. Clin J Pain. 2010;26(1):1-8.
43. New York State Department of Health press release: State Prescription Forms Reducing Fraud and Abuse. July 31, 2007.
44. Gourlay DL, Heit HA. Universal precautions revisited: managing the inherited pain patient. Pain Med. 2009;10(suppl 2):S115-S123.
45. Gourlay DL, Heit HA, Almahrezi A. Universal precautions in pain medicine: a rational approach to the treatment of chronic pain. Pain Med. 2005;6(2):107-112. (Pubitemid 40590522)
46. The use of opioids for the treatment of chronic pain: a consensus statement from the American Academy of Pain Medicine and the American Pain Society. Clin J Pain. 1997;13(1):6-8.
47. Chou R, Fanciullo GJ, Fine PG, et al. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain. 2009;10(2): 113-130.
48. Trescot AM, Helm S, Hansen H, et al. Opioids in the management of chronic non-cancer pain: an update of American Society of the Interventional Pain Physicians' (ASIPP) Guidelines. Pain Physician. 2008;11 (2 suppl):S5-S62. (Pubitemid 351682078)
49. Fishman S. Responsible Opioid Prescribing: A Physician's Guide. Federation of State Medical Boards.
50. Substance Abuse and Mental Health Services Administration. (2009). Results from the 2008 National Survey on Drug Use and Health: National Findings (Office of Applied Studies, NSDUH Series H-36, HHS Publication No. SMA 09-4434). Rockville, MD, 2008.
51. Sullivan MD, Edlund MJ, Fan MY, Devries A, Brennan Braden J, Martin BC. Risks for possible and probable opioid misuse among recipients of chronic opioid therapy in commercial and medicaid insurance plans: the TROUP Study. Pain. 2010;150(2):332-339.
52. Madras BK. Office of National Drug Control Policy: a scientist in drug policy in Washington, DC. Ann N Y Acad Sci. 2010;1187:370-402.
53. Babor TF, McRee BG, Kassebaum PA, Grimaldi PL, Ahmed K, Bray J. Screening, Brief Intervention, and Referral to Treatment (SBIRT): toward a public health approach to the management of substance abuse. Subst Abus. 2007;28(3):7-30. (Pubitemid 350243063)
54. Madras BK, Compton WM, Avula D, Stegbauer T, Stein JB, Clark HW. Screening, brief interventions, referral to treatment (SBIRT) for illicit drug and alcohol use at multiple healthcare sites: comparison at intake and 6 months later. Drug Alcohol Depend. 2009;99(1-3):280-295.
55. InSight Project Research G. SBIRT outcomes in Houston: final report on InSight, a hospital district-based program for patients at risk for alcohol or drug use problems. Alcohol Clin Exp Res. 2009;33(8): 1374-1381.
56. Quanbeck A, Lang K, Enami K, Brown RL. A cost-benefit analysis of Wisconsin's screening, brief intervention, and referral to treatment program: adding the employer's perspective. WMJ. 2010;109(1):9-14.
57. Estee S, Wickizer T, He L, Shah MF, Mancuso D. Evaluation of the Washington state screening, brief intervention, and referral to treatment project: cost outcomes for Medicaid patients screened in hospital emergency departments. Med Care. 2010;48(1):18-24.
58. Wiedemer NL, Harden PS, Arndt IO, Gallagher RM. The opioid renewal clinic: a primary care, managed approach to opioid therapy in chronic pain patients at risk for substance abuse. Pain Med. 2007;8(7): 573-584. (Pubitemid 47490213)
59. US Department of Justice Drug Enforcement Administration Office of Diversion Control. Questions and answers: state prescription drug monitoring programs. 2011. http://www.deadiversion.usdoj.gov/faq/rx-monitor.htm.
60. Alliance of States with Prescription Monitoring Programs. http://www.pmpalliance.org/.
61. Eadie JL. New York State's Triplicate Prescription Program. NIDA Res Monogr. 1993;131:176-193. (Pubitemid 23303268)
62. Reidenberg MM. Effect of the requirement for triplicate prescriptions for benzodiazepines in New York State. Clin Pharmacol Ther. 1991; 50(2):129-131.
63. Ross-Degnan D, Simoni-Wastila L, Brown JS, et al. A controlled study of the effects of state surveillance on indicators of problematic and non-problematic benzodiazepine use in a Medicaid population. Int J Psychiatry Med. 2004;34(2):103-123. (Pubitemid 39121802)
64. Simoni-Wastila L, Ross-Degnan D, Mah C, Gao X, et al. A retrospective data analysis of the impact of the New York triplicate prescription program on benzodiazepine use in medicaid patients with chronic psychiatric and neurologic disorders. Clin Ther. 2004;26(2):322-336. (Pubitemid 38339023)
65. Weintraub M, Singh S, Byrne L, Maharaj K, Guttmacher L. Consequences of the 1989 New York State triplicate benzodiazepine prescription regulations. JAMA. 1991;266(17):2392-2397.
66. Pradel V, Thirion X, Ronfle E, Masut A, Micallef J, Begaud B. Assessment of doctor-shopping for high dosage buprenorphine maintenance treatment in a French region: development of a new method for prescription database. Pharmacoepidemiol Drug Saf. 2004;13(7):473-481. (Pubitemid 38996858)
67. Glajchen M. Chronic pain: treatment barriers and strategies for clinical practice. J Am Board Fam Pract. 2001;14(3):211-218. (Pubitemid 32428688)
68. Carey N, Courtenay M. A review of the activity and effects of nurseled care in diabetes. J Clin Nurs. 2007;16(11C):296-304.
69. Goebel JR, Sherbourne CD, Asch SM, et al. Addressing patients' concerns about pain management and addiction risks. Pain Manag Nurs. 2010;11(2):92-98.
70. Trescot AM, Boswell MV, Atluri SL, et al. Opioid guidelines in the management of chronic non-cancer pain. Pain Physician. 2006;9(1): 1-39.
71. Katz NP, Sherburne S, Beach M, et al. Behavioral monitoring and urine toxicology testing in patients receiving long-term opioid therapy. Anesth Analg. 2003;97(4):1097-1102. (Pubitemid 37158696)
72. Cone EJ, Caplan YH, Black DL, Robert T, Moser F. Urine drug testing of chronic pain patients: licit and illicit drug patterns. J Anal Toxicol. 2008;32(8):530-543.
73. Couto JE, Webster L, Romney MC, Leider HL, Linden A. Use of an algorithm applied to urine drug screening to assess adherence to an oxycontin regimen. J Opioid Manag. 2009;5(6):359-364.
74. Passik SD, Schreiber J, Kirsh KL, Portenoy RK. A chart review of the ordering and documentation of urine toxicology screens in a cancer center: do they influence patient management? J Pain Symptom Manage. 2000;19(1):40-44. (Pubitemid 30067622)
75. Michna E, Jamison RN, Pham LD, et al. Urine toxicology screening among chronic pain patients on opioid therapy: frequency and predictability of abnormal findings. Clin J Pain. 2007;23(2):173-179. (Pubitemid 46145464)
76. Fleming MF, Balousek SL, Klessig CL, Mundt MP, Brown DD. Substance use disorders in a primary care sample receiving daily opioid therapy. J Pain. 2007;8(7):573-582. (Pubitemid 46991033)
77. Starrels JL, Becker WC, Alford DP, Kapoor A, Williams AR, Turner BJ. Systematic review: treatment agreements and urine drug testing to reduce opioid misuse in patients with chronic pain. Ann Intern Med. 2010;152(11):712-720.
78. Owen GT, Burton AW, Schade CM, Passik S. Urine drug testing: current recommendations and best practices. Pain Physician. 2012;15(3 suppl):ES119-ES133.
79. Peppin JF, Passik SD, Couto JE, et al. Recommendations for urine drug monitoring as a component of opioid therapy in the treatment of chronic pain [published online June 13, 2012]. Pain Med. 2012;13(7): 886-896. doi:10.1111/j.1526-4637.2012.01414.x.
80. Weiss RD, Potter JS, Fiellin DA, et al. Adjunctive counseling during brief and extended buprenorphine-naloxone treatment for prescription opioid dependence: a 2-phase randomized controlled trial. Arch Gen Psychiatry 2011;68(12):1238-1246.
81. Trafton J, Martins S, Michel M, et al. Evaluation of the acceptability and usability of a decision support system to encourage safe and effective use of opioid therapy for chronic, noncancer pain by primary care providers. Pain Med. 2010;11(4):575-585.